ClinicalTrials.gg
CompletedNCT07906171Updated Oct 30, 2026

Pharmacokinetics and Safety of Levornidazole Disodium Phosphate for Injection in Chinese Patients With Hepatic Impairment

A Phase 1 interventional study of Levornidazole Disodium Phosphate for Injection and Levornidazole Disodium Phosphate for Injection in Hepatic Impairment, sponsored by Yangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceutical Co. Ltd. Completed at 3 sites in China. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Yangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceutical Co. Ltd · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Registered 3 years 1 month after the study started (first participant enrolled Sep 2023, registered Oct 2026).
Updated Oct 30, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
25
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Objective: To evaluate the pharmacokinetics and safety of a single intravenous dose of levornidazole disodium phosphate for Injection in subjects with mild hepatic impairment (Child-Pugh A), moderate hepatic impairment (Child-Pugh B), and healthy subjects.

02

Conditions studied

  • Hepatic Impairment
03

In context

Lead sponsor

Yangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceutical Co. Ltd is the lead sponsor of 6 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  1. Inclusion Criteria (Subjects with Hepatic Impairment):

    • Male and female subjects aged 18 to 75 years (inclusive);
    • Male subjects with body weight ≥ 50.0 kg and female subjects with body weight ≥ 45.0 kg, with (BMI) [BMI = weight (kg) / height² (m²)] between 18.0 and 30.0 kg/m² (inclusive);
    • Subjects with hepatic impairment caused by pre-existing primary liver disease (excluding drug-induced liver injury), with classification of mild (Grade A) or moderate (Grade B);
    • Subjects who have had a stable medication regimen (including drug type, dosage, and frequency) for the treatment of hepatic impairment, complications of liver disease, and other concomitant diseases within 2 weeks prior to check-in or within 5 half-lives of concomitant medications (whichever is longer) through the end of the study period, without requiring adjustment, or subjects who were not on any medication prior to enrollment;
    • Subjects whose hepatic function status is assessed by the investigator as stable from 2 weeks prior to administration of the drug through the end of the study period, without significant deterioration (e.g., abdominal pain, ascites, nausea, vomiting, anorexia, fever, or worsening of liver function-related laboratory results);
    • Subjects of (including their partners) who voluntarily agree to use appropriate measures from 2 weeks prior to screening through 3 months after dosing, and who have no plans for sperm or egg donation;
    • Subjects who are able to understand and are willing to strictly comply with the clinical trial protocol to complete the study, and who have signed the form.
  2. Inclusion Criteria Healthy Subjects:

    • Male and female subjects aged 18 to 75 years (inclusive), matched with subjects in Groups A and B by age and gender;
    • Male subjects with body weight ≥ 50.0 kg and female subjects with body weight ≥ 45.0 kg, with body mass index (BMI) between 18.0 and 30.0 kg/m² (inclusive), matched with subjects in Groups A and B by BMI;
    • Normal hepatic function;
    • Subjects with normal results from medical history inquiry, physical examination, vital sign monitoring, 12-lead (ECG), laboratory tests (complete blood count, urinalysis, blood biochemistry, coagulation function), alpha-fetoprotein (AFP), abdominal ultrasound (liver, spleen, gallbladder, pancreas, bilateral kidneys, ascites), and other imaging examinations, or with abnormalities deemed clinically insignificant by the investigator;
    • Subjects of childbearing potential (including their partners) who voluntarily agree to use appropriate contraceptive measures from 2 weeks prior to screening through 3 months after dosing, and who have no plans for sperm or egg donation;
    • Subjects who are able to understand and are willing to strictly comply with the clinical trial protocol to complete the study, and who have signed the informed consent form.

Exclusion Criteria:

  1. Exclusion Criteria (Subjects with Hepatic Impairment):

    • Subjects with a confirmed allergy to Levornidazole Disodium Phosphate for Injection or any of its formulation components, or to other nitroimidazole drugs; or those with a history of drug or food allergies, or a history of specific atopic diseases (such as asthma, urticaria, eczema, etc.);
    • Subjects with special dietary requirements who cannot accept a unified diet;
    • Subjects with difficult venous blood sampling, inability to tolerate venipuncture, or a history of needle phobia or blood phobia;
    • Subjects who have undergone surgical procedures within 4 weeks prior to screening, or who plan to undergo surgery during the study period;
    • Subjects with a history of liver transplantation surgery;
    • Subjects with acute hepatic impairment or liver failure, or those with complications such as hepatic encephalopathy, hepatocellular carcinoma, esophageal and gastric variceal bleeding, spontaneous bacterial peritonitis, hepatorenal syndrome, etc.; or subjects with active (those who are HCV-Ab positive but have two HCV-RNA results below the lower limit of detection at an interval of 12 weeks or more may be enrolled); or subjects with active chronic (those who are HBsAg positive, HBeAg negative, and HBV-DNA \< 2×10³ IU/mL may be enrolled);
    • Subjects with diseases affecting bile excretion, such as biliary cirrhosis, biliary obstruction, or cholestatic liver disease;
    • Subjects with abnormal or syphilis screening results (those with syphilis antibody levels above the normal range but TRUST negative may be enrolled in this study);
    • Subjects with uncontrolled cardiac, respiratory, gastrointestinal, hematological, or neurological diseases, or other medical history that may affect the study results, as judged by the investigator;
    • Subjects whose laboratory test results at screening meet any of the following criteria: (a) (ALT) or aspartate aminotransferase (AST) > 10 × ; (b) (HGB) \< 60 g/L; (c) Abnormal alpha-fetoprotein (AFP) levels suggestive of hepatocellular carcinoma (in combination with other imaging examinations such as liver ultrasound, CT, or MRI);
    • Subjects with uncontrolled or poorly controlled hypertension (systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 100 mmHg);
    • Subjects with estimated (eGFR) \< 60 mL/min/1.73 m²;
    • Subjects with a history of drug abuse or substance use, or a positive urine drug screening result;
    • Subjects who are regular drinkers within 3 months prior to check-in, i.e., consuming more than 14 units of alcohol per week (1 unit ≈ 360 mL beer, or 45 mL of 40% spirit, or 150 mL wine), or those who cannot abstain from any alcoholic products during the study period, or those with an alcohol breath test result > 0 mg/100 mL;
    • Subjects who have donated blood or experienced significant blood loss (> 400 mL), or received blood transfusions or blood products within 3 months prior to check-in, or those who plan to donate blood during the study period or within 1 month after the end of the study;
    • Subjects who smoke ≥ 5 cigarettes per day within 3 months prior to check-in, or those who do not agree to abstain from any tobacco products during the study period;
    • Subjects who consume excessive tea, coffee, and/or caffeinated beverages (more than 8 cups per day, 1 cup ≈ 250 mL) within 3 months prior to check-in, or those who do not agree to abstain from such beverages during the study period;
    • Subjects who have participated in a clinical trial and received an investigational drug within 90 days prior to screening, or those who plan to participate in another clinical trial during the study period;
    • Subjects who have received vaccination within 30 days prior to screening, or those who plan to receive vaccination during the study period;
    • Subjects who have used any drugs that inhibit or induce CYP or UGT enzymes within 30 days prior to check-in;
    • Subjects who have used any prescription drugs, over-the-counter drugs, vitamins, or herbal medicines within 14 days prior to check-in, except for those used to treat hepatic impairment or their concomitant chronic diseases;
    • Subjects who have consumed a special diet (including grapefruit, chocolate, or foods/beverages rich in xanthine) within 48 hours prior to check-in;
    • Female subjects who are lactating or pregnant;
    • Subjects who have developed acute diseases from the screening period to before dosing;
    • Subjects who are deemed unsuitable for inclusion by the investigator.
  2. Exclusion Criteria (Healthy Subjects):

    • Subjects with a confirmed allergy to Levornidazole Disodium Phosphate for Injection or any of its formulation components, or to other nitroimidazole drugs; or those with a history of drug or food allergies, or a history of specific atopic diseases (such as asthma, urticaria, eczema, etc.);
    • Subjects with special dietary requirements who cannot accept a unified diet;
    • Subjects with difficult venous blood sampling, inability to tolerate venipuncture, or a history of needle phobia or blood phobia;
    • Subjects with any clinically significant abnormality in hepatitis B surface antigen (HBsAg), syphilis-specific antibody, human immunodeficiency virus antigen/antibody (HIV Ag/Ab), or hepatitis C virus antibody (HCV-Ab);
    • Subjects with a history of severe diseases of the respiratory, circulatory, digestive, urinary, hematological, endocrine, immune, neurological, or psychiatric systems;
    • Subjects who have undergone surgical procedures within 4 weeks prior to screening, or who plan to undergo surgery during the study period;
    • Subjects with a history of drug abuse or substance use, or a positive urine drug screening result;
    • Subjects who are regular drinkers within 3 months prior to check-in, i.e., consuming more than 14 units of alcohol per week (1 unit ≈ 360 mL beer, or 45 mL of 40% spirit, or 150 mL wine), or those who cannot abstain from any alcoholic products during the study period, or those with an alcohol breath test result > 0 mg/100 mL;
    • Subjects who have donated blood or experienced significant blood loss (> 400 mL), or received blood transfusions or blood products within 3 months prior to check-in, or those who plan to donate blood during the study period or within 1 month after the end of the study;
    • Subjects who smoke ≥ 5 cigarettes per day within 3 months prior to check-in, or those who do not agree to abstain from any tobacco products during the study period;
    • Subjects who consume excessive tea, coffee, and/or caffeinated beverages (more than 8 cups per day, 1 cup ≈ 250 mL) within 3 months prior to check-in, or those who do not agree to abstain from such beverages during the study period;
    • Subjects who have participated in a clinical trial and received an investigational drug within 90 days prior to screening, or those who plan to participate in another clinical trial during the study period;
    • Subjects who have received vaccination within 30 days prior to screening, or those who plan to receive vaccination during the study period;
    • Subjects who have used any drugs that inhibit or induce CYP or UGT enzymes within 30 days prior to check-in;
    • Subjects who have used any prescription drugs, over-the-counter drugs, health supplements, vitamins, or herbal medicines within 14 days prior to check-in;
    • Subjects who have consumed a special diet (including grapefruit, chocolate, or foods/beverages rich in xanthine) within 48 hours prior to check-in;
    • Female subjects who are lactating or pregnant;
    • Subjects who have developed acute diseases from the screening period to before dosing;
    • Subjects who are deemed unsuitable for inclusion by the investigator.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    levornidazole disodium phosphate for Injection (Mild Hepatic Impairment)

    Participants with mild hepatic impairment will receive a single dose of levornidazole disodium phosphate for Injection on Day 1.

    Drug: Levornidazole Disodium Phosphate for Injection

  • Experimental
    levornidazole disodium phosphate for Injection (Moderate Hepatic Impairment)

    Participants with Moderate hepatic impairment will receive a single dose of levornidazole disodium phosphate for Injection on Day 1.

    Drug: Levornidazole Disodium Phosphate for Injection

  • Experimental
    levornidazole disodium phosphate for Injection (Normal Hepatic Function)

    Participants with Normal Hepatic Function will receive a single dose of levornidazole disodium phosphate for Injection on Day 1.

    Drug: Levornidazole Disodium Phosphate for Injection

Interventions

  • DrugLevornidazole Disodium Phosphate for Injection

    Single dose,IV. ,0.5g,60 min(±5 min)

  • DrugLevornidazole Disodium Phosphate for Injection

    Single dose,IV. ,0.5g,60 min(±5 min)

  • DrugLevornidazole Disodium Phosphate for Injection

    Single dose,IV. ,0.5g,60 min(±5 min)

06

What researchers measure

Primary outcomes

  1. Area Under the Plasma Concentration-time Curve From Time 0 to the Last Measurable Concentration (AUC0-t) of levornidazole

    AUClast is defined as the concentration of drug from time zero to the last observable concentration.

    Time frame: From Day 1 to Day 5

  2. Area Under the Plasma Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-∞) of levornidazole

    AUCinf is defined as the concentration of drug extrapolated to infinite time.

    Time frame: From Day 1 to Day 5

  3. Maximum Observed Plasma Concentration (Cmax) of levornidazole

    Cmax is defined as the maximum concentration of drug.

    Time frame: From Day 1 to Day 5

Secondary outcomes

  1. Clearance (CL) of levornidazole

    CL is defined as the clearance following administration of the drug.

    Time frame: From Day 1 to Day 5

  2. The Volume of Distribution (Vd) of levornidazole

    Vd is defined as the volume of distribution of the drug.

    Time frame: From Day 1 to Day 5

  3. Time of Maximum Observed Plasma Concentration (Tmax) of levornidazole

    Tmax is defined as the time (observed time point) of Cmax.

    Time frame: From Day 1 to Day 5

  4. Apparent Terminal Elimination Half-life (t1/2) of levornidazole

    Time frame: From Day 1 to Day 5

  5. Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: From Day 1 to Day 9

07

Study locations

3 sites
  • Chengdu Fifth People's Hospital
    Chengdu, China
  • Sichuan Provincial People's Hospital
    Chengdu, China
  • Deyang People's Hospital
    Deyang, China
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2023 to primary completion in Sep 2024, 12 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 22, 2026
First posted
Oct 30, 2026
StartActual
Sep 15, 2023
Primary completionActual
Sep 21, 2024
CompletionActual
Nov 4, 2024
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07906171
Lead sponsor
Yangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceutical Co. Ltd
Collaborators
Chengdu Fifth People's Hospital
Responsible party
Sponsor
First posted
Oct 30, 2026
Start date
Sep 15, 2023
Primary completion
Sep 21, 2024
Completion
Nov 4, 2024
Last update
Oct 30, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion